Merck’s Sotatercept Clears Phase III Trial
Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein to stable background therapy resulted in a significant increase in exercise capacity measured using the six-minute walking test in PAH patients, meeting the trial’s primary objectives.
Furthermore, the drug met 8 of 9 secondary endpoints in the study, except for one that looked at the emotional and cognitive ...
